Targovax ASA invites investors, analysts and media to a Capital Markets Day on Thursday 18 February 2021
Based on the strong clinical data that are now generated on ONCOS-102, Targovax has a solid fundament to move into late stage clinical development. We also have a broader pipeline of preclinical assets that could create a broader horizon of opportunities in the future. The Capital Markets day will feature presentations updating the market on these aspects.
DATE Thursday, February 18, 2021
TIME 2:30 PM CET
LOCATION Virtual event – live streaming
REPLAY Available after the event
The agenda will be as follows:
Agenda & speakers
|2:30-2:40 PM||Welcome||Øystein Soug, CEO, Targovax|
|2:40-3:25 PM||Anti-PD1 refractory melanoma||Alexander N. Shoushtari, MD|
|3:25-3:45 PM||ONCOS-102 development program||Magnus Jäderberg, CMO, Targovax|
5 minutes break
|3:50-4:05 PM||Immune activation||Victor Levitsky, CSO, Targovax|
|4:05-4:15 PM||Preclinical pipeline update||Victor Levitsky, CSO, Targovax|
|4:15-4:25 PM||4Q update||Torbjørn Furuseth, CFO, Targovax|
|4:25 PM||Closing remarks||Øystein Soug, CEO, Targovax|
The presentations will be made available on the company´s website after the end of the meeting. Questions can be submitted through the webcast throughout the event.
Dr. Alexander Shoushtari is renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He is part of several immunotherapy trials at MSKCC and Dr. Alexander Shoushtari is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma.